Blueprint Medicines Corp Shares Fall 4.0% Below Previous 52-Week Low - Market Mover

The shares fell 4.0% lower than its previous 52-week low of $79.08, with trading volume higher than its 30 day average

Share
Tweet

Jan 14, 2022 by Kwhen Finance Editors

Blueprint Medicines Corp Shares Fall 4.0% Below Previous 52-Week Low - Market Mover
Blueprint Medicines Corp (BPMC) shares closed 4.0% lower than its previous 52 week low, giving the company a market cap of $4B. The stock is currently down 23.9% year-to-date, down 24.0% over the past 12 months, and up 152.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%.

Trading Activity

  • Trading volume this week was 40.0% higher than the 20-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
  • MACD, a trend-following momentum indicator, indicates a downward trend.
  • The stock closed above its Bollinger band, indicating it may be overbought.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $328 million in earnings before interest and taxes from $809 million in revenue. It currently holds $851 million in cash and $112 million in debt.
  • Its forward price-to-earnings (P/E) ratio of -13.769527855906393 is lower than its current P/E ratio of -11.67, implying that analysts are expecting an increase in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 0.09. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.16 which means it currently has $1.16 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 3.81. This means that the stock is trading at a premium of 4 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 6.59.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 5.53.

P/E

-11.67

EBITDA

$328M

P/Book

3.81

Mkt Cap

$4B

P/Sales

6.59

Revenue

$809M

EPS (TTM)

-6.96

PEG Ratio

0.09

EV/Revenue

5.53

Total Cash

$851M

Debt/Equity

1.16

Forward P/E

-13.77

Current Debt

$112M

Gross Profit

$808M

Dividend Date

-

Earnings Date

2022-02-16

Profit Margin

0.40

Revenue/Share

13.87

Total Revenue

$809M

Enterprise Val

$4B

Put/Call Ratio

0.56

Revenue/Employee

0.00

Market Comparative Performance

  • The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis
  • The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis
  • The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
Blueprint Medicines Corp-6.9-23.9-24.0-31.32.4
Dow Jones Industrial Average-0.5-0.118.8-1.424.0
S&P 500 Index-1.4-0.826.0-1.629.9
Health Care-1.8-3.815.2-4.522.7

Peer Group Comparative Performance

  • The company's stock price performance year-to-date lags the peer average by 111.8%
  • The company's stock price performance over the past 12 months beats the peer average by -52.1%
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
Blueprint Medicines CorpBPMC-11.7-23.9-24.0-31.32.4
Peer AvgN/A-11.6-11.3-50.1-66.114.2
Pacific Biosciences of California IncPACB-86.2-29.4-56.5-73.14.1
Opko Health IncOPK39.8-7.7-0.7-28.437.7
Aldeyra Therapeutics IncALDX0-6.8-65.5-76.411.6
IsoRay Inc.ISR0-1.3-77.8-86.43.6

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?

Tags: